spacer
home > ebr > summer 2019 > the renaissance of microbial fermentation
PUBLICATIONS
European Biopharmaceutical Review

The Renaissance of Microbial Fermentation

Initially, many smaller biologic drug substances − including recombinant proteins and peptides − were produced via microbial fermentation. However, with the advent of cell culture systems, interest shifted to mammalian systems to produce larger proteins and antibodies. Now, the introduction of smaller, complex next-generation molecules, such as bioconjugates, antibody fragments, and other scaffolds, are once again driving interest in fermentation as an effective manufacturing platform.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Dr Vladas Bumelis is the founder of Northway Biotechpharma and Chairman of the company’s Board of Directors and Advisory Board. He has extensive experience in the pharma and biotechnology industries, having previously served as General Manager of Teva Pharmaceutical Industries, Chairman of the Board for Biofa and Biotechna, and Chairman of the Board and General Manager of the Institute of Applied Enzymology in Lithuania. In 2004, Vladas received the Science Award of Lithuania in recognition of his achievements in the development and production of recombinant proteins. He has a PhD and MSc in chemistry, as well as a PhD in biotechnology, from Vilnius University, Lithuania.
spacer
Dr Vladas Bumelis
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals and Nordic Nanovector have extended partnership for Betalutin® late stage manufacturing for B-cell non-Hodgkin lymphoma (NHL) treatment

The non-Hodgkin lymphoma (NHL) is a cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system
More info >>

White Papers
 
Industry Events

ELRIG Drug Discovery 2019 – Looking Back to the Future

5-6 November 2019, ACC, Liverpool

Now in its 13th year, ELRIG’s flagship conference Drug Discovery 2019 will take place at ACC in Liverpool. This year’s focus, ‘A Look Back to the Future’ is planned to include plenary introductions assessing how we got to where we are now and setting the challenges for discovering the drugs of the future. These will be followed by cutting edge talks and examples of new directions in drug discovery. Our scientific programme will feature over 40 world-class speakers with 6 main session tracks. In partnership with key academic and charitable groups, we will also run joint disease and biology-oriented tracks focusing on the basic sciences that underpin successful drug discovery.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement